img

Global Endogenous Peptide Substances Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Endogenous Peptide Substances Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal Endogenous Peptide Substances Market
Global Endogenous Peptide Substances market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Endogenous Peptide Substances industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The driving force of endogenous peptides mainly comes from the following aspects
Biological functions of bioactive peptidesBioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and developmentWith the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technologySince the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indicationsAs the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
Report Covers
This report presents an overview of global Endogenous Peptide Substances market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Endogenous Peptide Substances market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides

Segment by Application


Research
Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Endogenous Peptide Substances introduction, etc. Endogenous Peptide Substances Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Endogenous Peptide Substances
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endogenous Peptide Substances Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Neuropeptides
1.2.3 Hormones
1.2.4 Cytokines
1.2.5 Peptide Hormones
1.2.6 Bioactive Peptides
1.3 Market by Application
1.3.1 Global Endogenous Peptide Substances Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Research
1.3.3 Medicine
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Endogenous Peptide Substances Market Perspective (2018-2033)
2.2 Global Endogenous Peptide Substances Growth Trends by Region
2.2.1 Endogenous Peptide Substances Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Endogenous Peptide Substances Historic Market Size by Region (2018-2023)
2.2.3 Endogenous Peptide Substances Forecasted Market Size by Region (2024-2033)
2.3 Endogenous Peptide Substances Market Dynamics
2.3.1 Endogenous Peptide Substances Industry Trends
2.3.2 Endogenous Peptide Substances Market Drivers
2.3.3 Endogenous Peptide Substances Market Challenges
2.3.4 Endogenous Peptide Substances Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Endogenous Peptide Substances by Players
3.1.1 Global Endogenous Peptide Substances Revenue by Players (2018-2023)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Players (2018-2023)
3.2 Global Endogenous Peptide Substances Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Endogenous Peptide Substances, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Endogenous Peptide Substances Market Concentration Ratio
3.4.1 Global Endogenous Peptide Substances Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endogenous Peptide Substances Revenue in 2022
3.5 Global Key Players of Endogenous Peptide Substances Head office and Area Served
3.6 Global Key Players of Endogenous Peptide Substances, Product and Application
3.7 Global Key Players of Endogenous Peptide Substances, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Endogenous Peptide Substances Breakdown Data by Type
4.1 Global Endogenous Peptide Substances Historic Market Size by Type (2018-2023)
4.2 Global Endogenous Peptide Substances Forecasted Market Size by Type (2024-2033)
5 Endogenous Peptide Substances Breakdown Data by Application
5.1 Global Endogenous Peptide Substances Historic Market Size by Application (2018-2023)
5.2 Global Endogenous Peptide Substances Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Endogenous Peptide Substances Market Size (2018-2033)
6.2 North America Endogenous Peptide Substances Market Size by Type
6.2.1 North America Endogenous Peptide Substances Market Size by Type (2018-2023)
6.2.2 North America Endogenous Peptide Substances Market Size by Type (2024-2033)
6.2.3 North America Endogenous Peptide Substances Market Share by Type (2018-2033)
6.3 North America Endogenous Peptide Substances Market Size by Application
6.3.1 North America Endogenous Peptide Substances Market Size by Application (2018-2023)
6.3.2 North America Endogenous Peptide Substances Market Size by Application (2024-2033)
6.3.3 North America Endogenous Peptide Substances Market Share by Application (2018-2033)
6.4 North America Endogenous Peptide Substances Market Size by Country
6.4.1 North America Endogenous Peptide Substances Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Endogenous Peptide Substances Market Size by Country (2018-2023)
6.4.3 North America Endogenous Peptide Substances Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Endogenous Peptide Substances Market Size (2018-2033)
7.2 Europe Endogenous Peptide Substances Market Size by Type
7.2.1 Europe Endogenous Peptide Substances Market Size by Type (2018-2023)
7.2.2 Europe Endogenous Peptide Substances Market Size by Type (2024-2033)
7.2.3 Europe Endogenous Peptide Substances Market Share by Type (2018-2033)
7.3 Europe Endogenous Peptide Substances Market Size by Application
7.3.1 Europe Endogenous Peptide Substances Market Size by Application (2018-2023)
7.3.2 Europe Endogenous Peptide Substances Market Size by Application (2024-2033)
7.3.3 Europe Endogenous Peptide Substances Market Share by Application (2018-2033)
7.4 Europe Endogenous Peptide Substances Market Size by Country
7.4.1 Europe Endogenous Peptide Substances Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Endogenous Peptide Substances Market Size by Country (2018-2023)
7.4.3 Europe Endogenous Peptide Substances Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Endogenous Peptide Substances Market Size (2018-2033)
8.2 China Endogenous Peptide Substances Market Size by Type
8.2.1 China Endogenous Peptide Substances Market Size by Type (2018-2023)
8.2.2 China Endogenous Peptide Substances Market Size by Type (2024-2033)
8.2.3 China Endogenous Peptide Substances Market Share by Type (2018-2033)
8.3 China Endogenous Peptide Substances Market Size by Application
8.3.1 China Endogenous Peptide Substances Market Size by Application (2018-2023)
8.3.2 China Endogenous Peptide Substances Market Size by Application (2024-2033)
8.3.3 China Endogenous Peptide Substances Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Endogenous Peptide Substances Market Size (2018-2033)
9.2 Asia Endogenous Peptide Substances Market Size by Type
9.2.1 Asia Endogenous Peptide Substances Market Size by Type (2018-2023)
9.2.2 Asia Endogenous Peptide Substances Market Size by Type (2024-2033)
9.2.3 Asia Endogenous Peptide Substances Market Share by Type (2018-2033)
9.3 Asia Endogenous Peptide Substances Market Size by Application
9.3.1 Asia Endogenous Peptide Substances Market Size by Application (2018-2023)
9.3.2 Asia Endogenous Peptide Substances Market Size by Application (2024-2033)
9.3.3 Asia Endogenous Peptide Substances Market Share by Application (2018-2033)
9.4 Asia Endogenous Peptide Substances Market Size by Region
9.4.1 Asia Endogenous Peptide Substances Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Endogenous Peptide Substances Market Size by Region (2018-2023)
9.4.3 Asia Endogenous Peptide Substances Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Type
10.2.1 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Application
10.3.1 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Country
10.4.1 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Details
11.1.2 Assertio Therapeutics Inc. Business Overview
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Introduction
11.1.4 Assertio Therapeutics Inc. Revenue in Endogenous Peptide Substances Business (2018-2023)
11.1.5 Assertio Therapeutics Inc. Recent Developments
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Details
11.2.2 Cipher Pharmaceuticals Inc. Business Overview
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Introduction
11.2.4 Cipher Pharmaceuticals Inc. Revenue in Endogenous Peptide Substances Business (2018-2023)
11.2.5 Cipher Pharmaceuticals Inc. Recent Developments
11.3 Endo International Plc
11.3.1 Endo International Plc Company Details
11.3.2 Endo International Plc Business Overview
11.3.3 Endo International Plc Endogenous Peptide Substances Introduction
11.3.4 Endo International Plc Revenue in Endogenous Peptide Substances Business (2018-2023)
11.3.5 Endo International Plc Recent Developments
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Details
11.4.2 Biosynth Carbosynth Business Overview
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Introduction
11.4.4 Biosynth Carbosynth Revenue in Endogenous Peptide Substances Business (2018-2023)
11.4.5 Biosynth Carbosynth Recent Developments
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Details
11.5.2 Lannett Co. Inc. Business Overview
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Introduction
11.5.4 Lannett Co. Inc. Revenue in Endogenous Peptide Substances Business (2018-2023)
11.5.5 Lannett Co. Inc. Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Endogenous Peptide Substances Introduction
11.6.4 Pfizer Revenue in Endogenous Peptide Substances Business (2018-2023)
11.6.5 Pfizer Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Endogenous Peptide Substances Introduction
11.7.4 Johnson & Johnson Revenue in Endogenous Peptide Substances Business (2018-2023)
11.7.5 Johnson & Johnson Recent Developments
11.8 Peptide Institute
11.8.1 Peptide Institute Company Details
11.8.2 Peptide Institute Business Overview
11.8.3 Peptide Institute Endogenous Peptide Substances Introduction
11.8.4 Peptide Institute Revenue in Endogenous Peptide Substances Business (2018-2023)
11.8.5 Peptide Institute Recent Developments
11.9 Abbexa
11.9.1 Abbexa Company Details
11.9.2 Abbexa Business Overview
11.9.3 Abbexa Endogenous Peptide Substances Introduction
11.9.4 Abbexa Revenue in Endogenous Peptide Substances Business (2018-2023)
11.9.5 Abbexa Recent Developments
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Details
11.10.2 Phoenix Pharmaceuticals Business Overview
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Introduction
11.10.4 Phoenix Pharmaceuticals Revenue in Endogenous Peptide Substances Business (2018-2023)
11.10.5 Phoenix Pharmaceuticals Recent Developments
11.11 Creative Peptides
11.11.1 Creative Peptides Company Details
11.11.2 Creative Peptides Business Overview
11.11.3 Creative Peptides Endogenous Peptide Substances Introduction
11.11.4 Creative Peptides Revenue in Endogenous Peptide Substances Business (2018-2023)
11.11.5 Creative Peptides Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Endogenous Peptide Substances Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Neuropeptides
Table 3. Key Players of Hormones
Table 4. Key Players of Cytokines
Table 5. Key Players of Peptide Hormones
Table 6. Key Players of Bioactive Peptides
Table 7. Global Endogenous Peptide Substances Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 8. Global Endogenous Peptide Substances Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Endogenous Peptide Substances Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Endogenous Peptide Substances Market Share by Region (2018-2023)
Table 11. Global Endogenous Peptide Substances Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Endogenous Peptide Substances Market Share by Region (2024-2033)
Table 13. Endogenous Peptide Substances Market Trends
Table 14. Endogenous Peptide Substances Market Drivers
Table 15. Endogenous Peptide Substances Market Challenges
Table 16. Endogenous Peptide Substances Market Restraints
Table 17. Global Endogenous Peptide Substances Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Endogenous Peptide Substances Revenue Share by Players (2018-2023)
Table 19. Global Top Endogenous Peptide Substances by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2022)
Table 20. Global Endogenous Peptide Substances Industry Ranking 2021 VS 2022 VS 2023
Table 21. Global 5 Largest Players Market Share by Endogenous Peptide Substances Revenue (CR5 and HHI) & (2018-2023)
Table 22. Global Key Players of Endogenous Peptide Substances, Headquarters and Area Served
Table 23. Global Key Players of Endogenous Peptide Substances, Product and Application
Table 24. Global Key Players of Endogenous Peptide Substances, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Endogenous Peptide Substances Revenue Market Share by Type (2018-2023)
Table 28. Global Endogenous Peptide Substances Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Endogenous Peptide Substances Revenue Market Share by Type (2024-2033)
Table 30. Global Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Endogenous Peptide Substances Revenue Share by Application (2018-2023)
Table 32. Global Endogenous Peptide Substances Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Endogenous Peptide Substances Revenue Share by Application (2024-2033)
Table 34. North America Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 35. North America Endogenous Peptide Substances Market Size by Type (2024-2033) & (US$ Million)
Table 36. North America Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 37. North America Endogenous Peptide Substances Market Size by Application (2024-2033) & (US$ Million)
Table 38. North America Endogenous Peptide Substances Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 39. North America Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 40. North America Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 41. Europe Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 42. Europe Endogenous Peptide Substances Market Size by Type (2024-2033) & (US$ Million)
Table 43. Europe Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 44. Europe Endogenous Peptide Substances Market Size by Application (2024-2033) & (US$ Million)
Table 45. Europe Endogenous Peptide Substances Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Europe Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 47. Europe Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 48. China Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 49. China Endogenous Peptide Substances Market Size by Type (2024-2033) & (US$ Million)
Table 50. China Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 51. China Endogenous Peptide Substances Market Size by Application (2024-2033) & (US$ Million)
Table 52. Asia Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 53. Asia Endogenous Peptide Substances Market Size by Type (2024-2033) & (US$ Million)
Table 54. Asia Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 55. Asia Endogenous Peptide Substances Market Size by Application (2024-2033) & (US$ Million)
Table 56. Asia Endogenous Peptide Substances Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 57. Asia Endogenous Peptide Substances Market Size by Region (2018-2023) & (US$ Million)
Table 58. Asia Endogenous Peptide Substances Market Size by Region (2024-2033) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Type (2024-2033) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Application (2024-2033) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Endogenous Peptide Substances Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 64. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 66. Assertio Therapeutics Inc. Company Details
Table 67. Assertio Therapeutics Inc. Business Overview
Table 68. Assertio Therapeutics Inc. Endogenous Peptide Substances Product
Table 69. Assertio Therapeutics Inc. Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 70. Assertio Therapeutics Inc. Recent Developments
Table 71. Cipher Pharmaceuticals Inc. Company Details
Table 72. Cipher Pharmaceuticals Inc. Business Overview
Table 73. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product
Table 74. Cipher Pharmaceuticals Inc. Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 75. Cipher Pharmaceuticals Inc. Recent Developments
Table 76. Endo International Plc Company Details
Table 77. Endo International Plc Business Overview
Table 78. Endo International Plc Endogenous Peptide Substances Product
Table 79. Endo International Plc Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 80. Endo International Plc Recent Developments
Table 81. Biosynth Carbosynth Company Details
Table 82. Biosynth Carbosynth Business Overview
Table 83. Biosynth Carbosynth Endogenous Peptide Substances Product
Table 84. Biosynth Carbosynth Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 85. Biosynth Carbosynth Recent Developments
Table 86. Lannett Co. Inc. Company Details
Table 87. Lannett Co. Inc. Business Overview
Table 88. Lannett Co. Inc. Endogenous Peptide Substances Product
Table 89. Lannett Co. Inc. Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 90. Lannett Co. Inc. Recent Developments
Table 91. Pfizer Company Details
Table 92. Pfizer Business Overview
Table 93. Pfizer Endogenous Peptide Substances Product
Table 94. Pfizer Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 95. Pfizer Recent Developments
Table 96. Johnson & Johnson Company Details
Table 97. Johnson & Johnson Business Overview
Table 98. Johnson & Johnson Endogenous Peptide Substances Product
Table 99. Johnson & Johnson Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 100. Johnson & Johnson Recent Developments
Table 101. Peptide Institute Company Details
Table 102. Peptide Institute Business Overview
Table 103. Peptide Institute Endogenous Peptide Substances Product
Table 104. Peptide Institute Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 105. Peptide Institute Recent Developments
Table 106. Abbexa Company Details
Table 107. Abbexa Business Overview
Table 108. Abbexa Endogenous Peptide Substances Product
Table 109. Abbexa Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 110. Abbexa Recent Developments
Table 111. Phoenix Pharmaceuticals Company Details
Table 112. Phoenix Pharmaceuticals Business Overview
Table 113. Phoenix Pharmaceuticals Endogenous Peptide Substances Product
Table 114. Phoenix Pharmaceuticals Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 115. Phoenix Pharmaceuticals Recent Developments
Table 116. Creative Peptides Company Details
Table 117. Creative Peptides Business Overview
Table 118. Creative Peptides Endogenous Peptide Substances Product
Table 119. Creative Peptides Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 120. Creative Peptides Recent Developments
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Endogenous Peptide Substances Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Endogenous Peptide Substances Market Share by Type: 2022 VS 2033
Figure 3. Neuropeptides Features
Figure 4. Hormones Features
Figure 5. Cytokines Features
Figure 6. Peptide Hormones Features
Figure 7. Bioactive Peptides Features
Figure 8. Global Endogenous Peptide Substances Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 9. Global Endogenous Peptide Substances Market Share by Application: 2022 VS 2033
Figure 10. Research Case Studies
Figure 11. Medicine Case Studies
Figure 12. Others Case Studies
Figure 13. Endogenous Peptide Substances Report Years Considered
Figure 14. Global Endogenous Peptide Substances Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Endogenous Peptide Substances Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Endogenous Peptide Substances Market Share by Region: 2022 VS 2033
Figure 17. Global Endogenous Peptide Substances Market Share by Players in 2022
Figure 18. Global Top Endogenous Peptide Substances Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Endogenous Peptide Substances Revenue in 2022
Figure 20. North America Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Endogenous Peptide Substances Market Share by Type (2018-2033)
Figure 22. North America Endogenous Peptide Substances Market Share by Application (2018-2033)
Figure 23. North America Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 24. United States Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Canada Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Endogenous Peptide Substances Market Size YoY (2018-2033) & (US$ Million)
Figure 27. Europe Endogenous Peptide Substances Market Share by Type (2018-2033)
Figure 28. Europe Endogenous Peptide Substances Market Share by Application (2018-2033)
Figure 29. Europe Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 30. Germany Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. France Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. U.K. Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Italy Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Russia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Nordic Countries Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. China Endogenous Peptide Substances Market Size YoY (2018-2033) & (US$ Million)
Figure 37. China Endogenous Peptide Substances Market Share by Type (2018-2033)
Figure 38. China Endogenous Peptide Substances Market Share by Application (2018-2033)
Figure 39. Asia Endogenous Peptide Substances Market Size YoY (2018-2033) & (US$ Million)
Figure 40. Asia Endogenous Peptide Substances Market Share by Type (2018-2033)
Figure 41. Asia Endogenous Peptide Substances Market Share by Application (2018-2033)
Figure 42. Asia Endogenous Peptide Substances Market Share by Region (2018-2033)
Figure 43. Japan Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. South Korea Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. China Taiwan Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Southeast Asia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. India Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Australia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Size YoY (2018-2033) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Share by Type (2018-2033)
Figure 51. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Share by Application (2018-2033)
Figure 52. Middle East, Africa, and Latin America Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 53. Brazil Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Mexico Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Turkey Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Saudi Arabia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Israel Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. GCC Countries Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 59. Assertio Therapeutics Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 60. Cipher Pharmaceuticals Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 61. Endo International Plc Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 62. Biosynth Carbosynth Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 63. Lannett Co. Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 64. Pfizer Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 65. Johnson & Johnson Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 66. Peptide Institute Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 67. Abbexa Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 68. Phoenix Pharmaceuticals Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 69. Creative Peptides Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries